Skip to main content

Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC

*March 2020*

Osimertinib (Tagrisso) is the standard frontline therapy for patients with metastatic, EGFR-mutant non–small cell lung cancer (NSCLC), and although the drug can provide years of benefit, more options beyond chemotherapy are needed for those who progress on this treatment, according to Erin M. Bertino, MD.